The introduction of biologic disease-modifying drugs changed the treatment of multiple sclerosis (MS) from a strategy directed at managing symptoms to one aimed at preventing relapses and hopefully progressive damage and achieving a state of no disease activity. However, early diagnosis, prompt intervention,and maintenance of tight symptoms control are known to be key in superior quality of life (QOL) and in preventing complications that may be independent of disease activity. In many cases the symptoms presentation, assessment and therapeutic interventions are shared between different neurological diseases,our program will be present the specifics of MS pathology. In this program we will demonstrate what can be done to mitigate or improve the outcomes in a variety of symptoms including: managing motor impairment, neurogenic bladder,bowel, and sexual dysfunction during first day and issues related to critical care of patients with neurological diseases including MS.
- Increase level of knowledge in treating spasticity, walking difficulties and bladder, bowel, and sexual dysfunction.
- Discuss and define the neurocritical care knowledge for neurological diseases.
- Initiate early diagnosis of symptoms that need evaluation and treatment in MS patients, knowing that early treatment improves patient outcomes.
Carolina Ionete, MD, PhD
Peter Riskind, MD, PhD
Paula Bellin, MD
Susan Bennett, PR, DPT, EdD, NCS, MSCS
Roberto Bomprezzi, MD, PhD
Riley Bove, MD
Jeremy J. Darlilng, LMHC
David Jones, MD
Frank Sup, PhD
Richard van Emmerick, PhD